SCHEMBL2238583

SCHEMBL2238583

COc1c(CC(=O)O)cccc1C(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.49
▸ ABCB11 O95342 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ ADORA1 P30542 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ MMP2 P08253 3/20 0.45
▸ MMP12 P39900 3/20 0.45
▸ MMP8 P22894 2/20 0.45
▸ MMP13 P45452 2/20 0.45
▸ MMP14 P50281 2/20 0.45
▸ MMP16 P51512 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HPGD P15428 2/20 0.43
▸ AKR1C3 P42330 1/20 0.43
▸ AKR1B1 P15121 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235848 0.88 MAPT (0.42) LMNAABCB11PTGS1ADORA1PTGS2
SCHEMBL9427409 0.85 MAPT (0.44) LMNAKDM4EMAPTMAPK1HSD17B10
SCHEMBL29324841 0.83 BCAT2 (0.45) LMNAABCB11PTGS1ADORA1PTGS2
SCHEMBL31346659 0.83 BCAT2 (0.45) LMNAABCB11PTGS1ADORA1PTGS2
SCHEMBL15391580 0.82 PPARG (0.46) LMNAKDM4EMAPTMAPK1HSD17B10
SCHEMBL9079419 0.82 AKR1B1 (0.52) LMNAPTGS2MMP2MMP12MMP8
SCHEMBL9427493 0.81 MAPT (0.43) LMNAKDM4EMAPTMAPK1HSD17B10
SCHEMBL31299650 0.81 CNR2 (0.46) LMNAPTGS2KDM4EMAPTMAPK1
SCHEMBL27684778 0.81 CNR2 (0.46) LMNAPTGS2KDM4EMAPTMAPK1
SCHEMBL56318 0.80 BCAT2 (0.56) LMNAABCB11PTGS1ADORA1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590314-B1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ FARMACEUTICI S P A (IT) 2015-08-05 — — EP claimed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 — — US claimed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 — — US claimed
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPÉ FARMACEUTICI S.P.A. (IT) 2006-10-05 — — US claimed
EP-1590314-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe' S.P.A. (IT) 2005-11-02 — — EP claimed
WO-2004069782-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2004-08-19 — — WO claimed
EP-1590314-B1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ FARMACEUTICI S P A (IT) 2015-08-05 — — EP disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 — — US disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 — — US disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 — — US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 — — US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 — — US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 — — US disclosed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 — — US disclosed
US-7776909-B2 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPE PHA.R.MA S.P.A. (IT) 2010-08-17 — — US disclosed
US-7776909-B2 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPE PHA.R.MA S.P.A. (IT) 2010-08-17 — — US disclosed
US-7776909-B2 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPE PHA.R.MA S.P.A. (IT) 2010-08-17 — — US disclosed
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPÉ FARMACEUTICI S.P.A. (IT) 2006-10-05 — — US disclosed
EP-1590314-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe' S.P.A. (IT) 2005-11-02 — — EP disclosed
WO-2004069782-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2004-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CXCR2, MMP8, CXCR1 LMNA 4305/4885ABCB11 3517/4885PTGS1 128/4885
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia CXCR2, CXCR1, MMP8 LMNA 4407/4885ABCB11 4242/4885PTGS1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback